IN RESPONSE:
We appreciate Dr. Janssen and colleagues' comments. They raise some important and valid concerns, which we address below.
As Dr. Janssen and colleagues point out, prediction rules are important to guide clinical practice in many instances, because they provide absolute risks for individual patients that can be used to determine treatment choices or further diagnostic work-up. We agree that before any rule can be adopted, it must be properly validated (which we did not do in our initial study) and must be derived from solid methodology.
It may be true that the c-statistic may not be the most sensitive measure of how much an additional variable contributes to estimates of individual risk. However, because the overall c-statistic for the final model with 3 variables was 0.943 (corresponding to the area under the receiver-operating characteristic curve), it is unlikely that any other significant predictors were missed by using this method.
We also agree with Dr. Janssen and colleagues' second point. The low event rate in our study reflects the reality seen in the few diagnostic studies of DVT in pregnant women. The prevalence of DVT in this particular cohort of patients is low (Ͻ10%). Despite our best efforts over 7 years, we were limited to 17 events (out of 194 patients). The rule that one should have 5 to 10 events per variable in a multivariable logistic model is based on the fact that having fewer events leads to unstable variable estimates. Thus, it would have been unreasonable to attempt to fit a single model with 11 independent variables to our data, but this does not imply that there is a problem with fitting 11 single-variable models.
The last comment by Dr. Janssen and colleagues is also valid. Our 2 objectives were to determine how clinicians find DVT in pregnant patients by subjective means and whether any "objective" predictors exist that can help clinicians to do this. We believe that we have achieved both objectives. We share all the concerns raised by Dr. Janssen and colleagues, including those regarding the development of prediction rules. We repeatedly emphasized throughout our article that this rule should not be applied in daily practice until it has been properly validated.
In pregnant women, symptoms mimicking DVT are common (for example, leg swelling and pain). At the very least, our study will increase awareness that when certain symptoms (for example, left leg presentation and asymmetry) are present, one should be more vigilant for the presence of DVT and arrange for appropriate testing. 
Wee-Shian Chan, MD, MSc

The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation
TO THE EDITOR: With regard to the article by Singer and colleagues (1), calculating net clinical benefit of warfarin therapy in atrial fibrillation is an important concept (2). However, 3 other issues should be considered in the future.
First, warfarin therapy affects other major events and may substantially reduce myocardial infarction and death (3) .
Second, because control of the international normalized ratio (INR) varies in different settings and because a 10% improvement in the amount of time the INR is in the therapeutic range (TTR) has been associated with a greater than 10% reduction in event rates (3, 4) , the relationship between INR control and event rates must be more thoroughly defined before it can be determined how INR control may affect the net clinical benefit in one's own setting. Veeger and colleagues (5) found that the bottom quartile of approximately 4000 patients was in range only 10% to 20% of the time and accounted for more than half of the major events. Jones and colleagues (4) found that the bottom quartile of 2223 patients was in range only about 28% of the time. Furthermore, because event rates increase exponentially as the INR moves further out of range, being slightly out of the target range may have little effect, whereas being at the extremes (INR, Ͻ1.5 or Ͼ5.0) may carry a very high risk. Therefore, one must know what the event rates were when the INR was in the target range TTR Ϯ 0.3 INR units, below an INR of 1.5, and above an INR of 5.0 to estimate the net clinical benefit in one's own setting.
Third, one must consider how evolving methods to improve INR control may alter the net clinical benefit. As noted by Hart and Halperin (2), the TTR of 65% reported by Singer and colleagues is often considered "high." By combining INR self-testing and computer management, however, Harper and Pollock (6) reported an 80% TTR with no INRs greater than 5. An interim analysis of our similar study (7) found a TTR of 78.9%, which increased to 94% when the range was expanded slightly by Ϯ0.3 INR units. Approximate TTR values were 90% for the top quartile and 60% for the lowest quartile, and the percentage of time that the INR was greater than 5 or less than 1.5 was only 0.27%. Such improved INR control is estimated to yield a 30% to 50% reduction in both thromboembolic and major bleeding events compared with "typical" management-changes that should have a substantial effect on the net clinical benefit of warfarin. TO THE EDITOR: Current guidelines from the American College of Cardiology/American Heart Association recommend that warfarin be given to patients with atrial fibrillation on the basis of stroke risk. This strategy maximizes stroke reduction only if the effect of warfarin is uniform across all risk factors. Singer and colleagues (1) present data that suggest otherwise. Their subgroup analysis found that men and women with atrial fibrillation have markedly different relative risk reductions when treated with warfarin (adjusted relative risk reduction, about 34% in men vs. 55% in women). Formal testing for treatment by covariate interaction (not reported by the authors) might confirm that the benefit of warfarin varies substantially in different subgroups of patients. Although female sex is not currently considered an indication for warfarin, the data suggest that certain patient subgroups may reap greater benefit from warfarin therapy than others. The presence of hypertension supports the use of warfarin according to current guidelines, but subgroup analysis shows little, if any, additional benefit in patients with hypertension compared with those without hypertension (absolute stroke reduction with warfarin, 1.11 per 100 person-years in patients with hypertension vs. 0.95 per 100 person-years in patients without hypertension). An optimum strategy for stroke reduction in patients with atrial fibrillation should be based not on factors that imply a high risk for stroke (as recommended by current guidelines), but rather on factors that imply a greater benefit of treatment. IN RESPONSE: We support Dr. Bussey's emphasis on the importance of maximizing TTR. The benefits and risks of warfarin therapy in atrial fibrillation are strongly dependent on maintaining the INR in the optimum range (1, 2) . That is why we reported the overall TTR, 65%, for our ATRIA (AnTicoagulation and Risk Factors In Atrial Fibrillation) cohort. At lower TTR values, the expected net clinical benefit will be lower, and at higher TTR values, the net clinical benefit will increase regardless of clinical risk category as long as the distribution of out-of-range values does not change markedly. As pointed out, having more extreme out-of-range low or high INR values will have a strong negative effect on the net benefit conferred by any given level of TTR. It is remarkable that warfarin's striking efficacy has been shown in studies in which the INR was in range only about two thirds of the time (for example, in the BAFTA [Birmingham Atrial Fibrillation Treatment of the Aged Study] trial [3] ). Substantially higher overall TTRs can be achieved in selected populations (2) . More widespread use of organized anticoagulation management services, INR self-testing, improved dosing algorithms, and possibly genetic testing for warfarin sensitivity all have the potential to effect more widespread improvement in TTRs and to increase net clinical benefit in patients with atrial fibrillation.
Henry Bussey, PharmD
The final sentence in Dr. Budhraja's letter aptly summarizes the motivation for our article. To generate an optimum estimate of the adjusted absolute net benefit of warfarin therapy, we allowed the effect of warfarin to vary by patient subgroup in our models, independent of the statistical significance of any individual interaction term. In fact, most of the interaction terms were not statistically significant and, except for the lowest stroke-risk categories, the interaction effects were small. Before firm conclusions that the relative risk reduction conferred by warfarin differs in any specific subgroup are drawn, such effect modification should be confirmed in other large databases, especially those from randomized trials.
As Dr. Budhraja notes, ischemic stroke risk off warfarin is only one determinant of net clinical benefit, but it is a very important one. Unfortunately, current risk stratification schemes for patients with atrial fibrillation have very limited accuracy (4). Future research should emphasize improved risk prediction in atrial fibrillation. Better risk prediction will facilitate achieving increased net benefit of warfarin at both the population and individual patient levels.
Comparing Costs and Quality of Care at Retail Clinics With Those of Other Medical Settings
TO THE EDITOR: I read the article by Mehrotra and colleagues (1) with great interest; however, I do have some concerns. First, the study compares episodes in patients who were first seen in different clinical settings (retail clinic, physician office, urgent care clinic, and emergency department). Patients may not have received care in the same clinical setting throughout the episode. Although the authors mention that the percentages of episodes with any follow-up visits were similar for retail clinics, urgent care centers, and physician offices and higher for emergency departments, we do not have information on the number of follow-up visits or the clinical settings in which they were conducted. Several patients who were first seen in retail clinics may have received follow-up in urgent care clinics or physician offices. Therefore, the quality-of-care measures and preventive services attributed to retail clinics could have been due to follow-up in other clinical settings.
Second, the study participants were matched by diagnosis codes but not by severity of symptoms, leading to a high likelihood of selection bias. It is possible that patients who initially visited a retail clinic had less-severe illness, and most may not have required laboratory testing or prescription medications. The overall cost for these patients may have been even lower if they were first seen in an urgent care clinic or a physician's office, because the higher cost of evaluation in these settings would be balanced by the money saved on unnecessary laboratory testing and medications.
Finally, the authors matched the study participants by income category but not by race or geographic location. Retail clinics are more likely to be present in areas with higher median income and lower population percentage of black persons and are less likely to exist in medically underserved areas (2) . Therefore, the population served by the retail clinics may differ significantly from that served by urgent care clinics and physician offices, even though all patients had the same health plan.
Rajan Kochar, MD, MPH University of Texas Health Science Center at Houston Houston, TX 77030
Potential Conflicts of Interest: None disclosed.
TO THE EDITOR:
The outcomes measured by Mehrotra and colleagues (1) show the fundamental weaknesses of retail clinics. Otitis media and pharyngitis are self-limited conditions whose clinical courses are not substantially altered by medical interventions in most cases. Many physicians in other developed countries do not commonly prescribe antibiotics for otitis media (2, 3) or pharyngitis (4).
Many retail clinics display a menu of diagnoses with prices. If a patient truly has one of these conditions, Mehrotra and colleagues successfully showed that the quality of care provided by retail clinics for these conditions is probably reasonable. I have heard stories from persons who have visited these clinics who tell me that no matter what the presenting set of circumstances, the patient will usually be diagnosed with one of the conditions on the menu.
Drawing conclusions on the basis of diagnosis codes from the International Classification of Diseases, Ninth Edition, misses the point. The quality issue is how an undifferentiated symptom, such as lower abdominal pain, is managed, not how a urinary tract infection is treated. If primary care clinics in the United States used the International Classification of Primary Care codes, such research could probably occur without having to look through thousands of charts (5) .
Ultimately, retail clinics will probably neither help nor hurt U.S. health care in any measureable way. With 75% of health care expenditures attributable to chronic diseases (6), the method of treating a self-limited sore throat is of little consequence. 
Although intended primarily as a comparison of retail clinics with other medical settings, the study by Mehrotra and colleagues (1) incidentally documents disturbing lapses in management of urinary tract infections in the comparison standard. Thus, the observed noninferiority of retail clinics says less about the adequacy of these clinics' performance than about the inadequate performance of the traditional care settings studied. Specifically, in the physician office, urgent care, and emergency department groups, more than 40% of high-risk patients had no urine culture done (despite the known greater diversity of pathogens and higher likelihood of antimicrobial resistance in such patients), antibiotics were prescribed for longer than 7 days for more than 40% of patients with uncomplicated cystitis (in whom high-quality evidence supports 3-day therapy [2] ), and more than 40% of patients with complicated urinary tract infections received less than 7 days of therapy (whereas expert opinion and some clinical trial evidence support longer treatment durations). Little comfort is provided by knowing that retail clinics are not doing any worse than traditional care settings for management of urinary tract infections when the traditional settings are doing so poorly; on the contrary, the latter finding is quite concerning.
James R. Johnson, MD Veterans Affairs Medical Center Minneapolis, MN 55417
IN RESPONSE: Dr. Kochar is correct that the follow-up care of an episode at a retail clinic could occur at another care site. But we doubt that this affected our quality scores. Fewer than 20% of episodes included any follow-up visits. Also, our quality measures generally focused on care around the first visit. For example, we looked at antibiotic prescriptions for otitis media that were filled on the day of the first visit or in the subsequent 2 days.
We shared Dr. Kochar's concern that patients who presented to a physician's office could be more ill and that this might drive some of the cost differences we observed. Yet, our sensitivity analyses that directly addressed this issue did not support this concern. The major driver of cost differences is reimbursement for the first visit. Costs that are probably related to severity of illness (for example, laboratory costs and follow-up visits) were less important. Nonetheless, as we note in our article, residual differences could exist between the patient populations at the care sites, although we feel that matching on income, level of illness, and insurance plan minimizes these differences.
Although we agree with Dr. Young that most cases of otitis media and pharyngitis are self-limited, 11.4% of all pediatric primary care visits are for just these 2 problems (1). Seeking care for these problems is the established norm in our society, and it is unclear whether this is a fair criticism of retail clinics. We agree that retail clinics are not a magic bullet for reduction of health care costs. In our own models, we estimate that $2 billion in cost savings would result if retail clinics become widespread, which constitutes less than 0.1% of health care spending.
We disagree with Dr. Young that the more important quality issue is how undifferentiated symptoms, such as lower abdominal pain, are managed. Proper management of uncomplicated urinary tract infections is an important issue and is the subject of much research and several guidelines (2) . Also, our goal was to compare the care at retail clinics with that of other care sites, and retail clinics do not manage undifferentiated abdominal pain.
Consistent with our previous work (3), our current study does find problems with quality across all the care sites. We agree with Dr.
Johnson that efforts to improve quality of care across the health care system are critical. potential adverse drug reaction. In fact, one standard drug reference (4) states that metformin is odorless.
Although reaction to the odor of metformin has not been reported in the medical literature, hundreds of postings to message boards on the Internet (5-8) note the peculiar odor of the drug, which is also well known to pharmacists. In an informal survey of several pharmacists (including the 2 pharmacist coauthors), all agreed that they could readily identify metformin by the odor, which was variously described as fishy or "like old locker-room sweat socks." The odor reportedly varies considerably between generic versions and seems to be less noticeable with film-coated (extended-release) formulations. Although Brittain (4) states metformin is odorless, Bristol-Myers Squibb, the manufacturer of Glucophage, is aware of complaints about odor (Liang J, May JR. Personal communication.).
We wonder why this reaction to metformin has not been previously reported. Patients may report that metformin nauseates them but do not further elaborate or distinguish this as a visceral reaction to the smell of the medication. Physicians probably interpret the report of nausea in light of well-known gastrointestinal side effects of the medication and do not pursue the issue further.
Our cases show that the distinctive odor of metformin (independent of other, well-known gastrointestinal adverse effects of the medication) causes patients to stop taking the drug. The effect seems to be certain, but idiosyncratic and patient dependent. This is a nonpharmacologic adverse effect of the drug.
When patients stop taking metformin, physicians should consider inquiring more closely about revulsion to the odor of the medication. Trial of a film-coated, extended-release formulation may be a reasonable approach in such cases. Further research is needed to determine whether odor revulsion is a common but heretofore unrecognized reason for discontinuation of metformin.
